Petra Acquisition, Inc. (NASDAQ:PAIC), in a press release today regarding it’s Phase 2b trials for REVTx-99, also announced that its shareholders approved its combination with biotech firm Revelation Biosciences in a meeting held last week.
Unfortunately, nothing has been filed yet and Petra did not disclose much information regarding the deal, including redemption figures. However, the combined company is expected to begin trading today on the Nasdaq under “REVB” and “REVBW”.
The SPAC recently added forward purchase agreements and a convertible note that added up to $12 million to its combination with Revelation. Of this amount, $4.5 million is to be used to backstop potential redemptions with financing from AXA Prime Impact Master Fund, LifeSci Venture Partners as well as other Petra and Revelation institutional investors. Meteora Capital and affiliates have also agreed to purchase 750,000 shares from redeeming shareholders and have agreed not to redeem themselves.
Petra initially announced its $128 million combination with Revelation on August 30. San Diego-based Revelation is developing two drug candidates aimed at treating respiratory diseases as well as a diagnostic device for diagnosing viral infections.
On December 1, it initiated Phase 2b trials for REVTx-99 to test its efficacy in treating the flu while this drug began Phase 1b trials for treating allergic rhinitis and chronic nasal congestion the month before.
ADVISORS
- Roth Capital Partners is acting as financial advisor to Revelation
- LifeSci Capital is acting as financial and capital markets advisor to Petra
- Loeb & Loeb LLP is acting as legal counsel to Petra
- Fox Rothschild LLP and J.P. Galda & Co are acting as legal counsel to Revelation
At the SPAC of Dawn Fed Chair Jerome Powell announced yesterday that the body intends to keep rates unchanged, earning him the moniker “FOOL” by US President Donald Trump. But, the announcement could bring some stability to market, which has seen macro factors pull it a variety of directions since the start of the year....
Tariffs, Trade Routes, and Tech: Freightos’ View from the Cargo Frontlines 2025 is shaping up to be a wild year for global trade, and few companies have a vantage point on the impacts of every-changing tariff policy quite like digital cargo-booking platform Freightos (NASDAQ:CRGO). This week, we catch up with Freightos CEO Zvi Schreiber. He shares...
NMP (NASDAQ:NMPU) has filed for a $100 million SPAC to conduct a broad search for a target, leveraging its team’s past consultancy work. The new SPAC’s units are set to contain one right to a 1/5 share. That is more generous to investors than the unit structure for Maxim Group’s other new SPAC filing this...
At the SPAC of Dawn Futures are green ahead of the Fed Chair Jerome Powell’s highly anticipated press conference at 2:30 pm ET today following two days of Federal Reserve meetings. Several other Fed members are expected to speak on Friday, but any news on rate changes is likely to come out of today’s speech,...
Dune Acquisition Corporation II (NASDAQ:IPODU) announced the pricing of its $125 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “IPODU”, Wednesday, May 7, 2025. The new SPAC aims expects to conduct a broad search for a combination target, but is interested in companies that are in the...